DECN - Decision Diagnostics Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0186
-0.0014 (-7.00%)
At close: 3:22PM EST
Stock chart is not supported by your current browser
Previous Close0.0200
Open0.0200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0186 - 0.0200
52 Week Range0.0100 - 0.0600
Volume74,100
Avg. Volume202,559
Market Cap2.503M
Beta (3Y Monthly)2.66
PE Ratio (TTM)N/A
EPS (TTM)-0.0370
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE17 days ago

    DECN Subsidiary Receives 510k Submission And ''K'' Numbers from FDA CDRH for Its Genchoice! Test Strip at the Close of the Government Shutdown

    LOS ANGELES, CA / ACCESSWIRE / January 30, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company's current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. Today the company announces that they have received formal FDA CDRH notification that the GenChoice! test strip 510K application submission has been accepted and routed for review.

  • ACCESSWIRElast month

    DECN Discusses Its Panacea GenUltimate! TBG System, Offering Elite Performance And Premier Upgrade Path For 4+ Million Users Of Lifescan Ultra Meters

    LOS ANGELES, CA / ACCESSWIRE / January 17, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 17 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company's current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. Today the company wishes to share expounded details regarding its new GenUltimate! panacea technology which will be used in the manufacture of its current GenUltimate! glucose test strip, its GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats and horses, and the GenUltimate! TBG test strip and Precise meter, the company's panacea product designed to achieve a new standard in at-home diabetes testing.

  • ACCESSWIRE2 months ago

    DECN Subsidiaries Appeal Nevada District Court Trial Judge's Ruling to U.S. Court of Appeals for the Federal Circuit (The Patent Appeals Court)

    LOS ANGELES, CA / ACCESSWIRE / December 19, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 16 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company's current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses. Decision Diagnostics through its subsidiary corporations PharmaTech Solutions, Inc. and Decision IT Corp. announces today that the companies have appealed the court decision in its case against Johnson & Johnson (JNJ) and two Lifescan divisions, Nevada U.S. District Court case 2:2016cv00564, to the U.S. Court of Appeals for the Federal Circuit in Washington, DC.

  • ACCESSWIRE2 months ago

    DECN Engages Second Korean Manufacturing Partner to Raise Its Factory Capacity by Two Million Boxes of ''GEN'' Test Strips Annually

    LOS ANGELES, CA / ACCESSWIRE / December 17, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) Decision Diagnostics Corp. is a 16 year olddiabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of glucose test strips and meters as highly accurate alternatives for legacy diabetic, proprietary, and pet testing glucose test strips. The company’s current portfolio of test strips includes its GenUltimate!, GenChoice!, GenSure!, and GenUltimate! TBG test strips, its Avantage! and Precise! Glucometers, and its PetSure! and GenUltimate! 4Pets testing products for dogs, cats and horses.

  • ACCESSWIRE2 months ago

    DECN Releases its Strategic IP And Product Development Introduction Plan With a Summary of 2018 Achievements and 2019 Expectations

    LOS ANGELES, CA / ACCESSWIRE / December 11, 2018 / Decision Diagnostics Corp. (OTC:PINK: DECN) Decision Diagnostics Corp. is a 16 year old diabetes focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for a growing brand of alternatives to legacy diabetic, proprietary, and pet testing glucose test strips. Decision Diagnostics is pleased to announce and communicate significant updates for several of our product lines including our GenChoice ("Ladybug"), GenPrecis! and GenPrecis! Precise Meter ("Dragonfly"), the PetSure! Test Strip ("small Ladybug"), the PetUltimate! Test Strip and PetUltimate! Avantage Meter ("Carnation").

  • ACCESSWIRE2 months ago

    DECN Receives Completed Clinical Trials Report from its IRB and Anticipates Filing its U.S. FDA 510k Application for its Genchoice! Product on December 21, 2018

    DECN to Launch Genchoice! Product in Select International Markets January 2, 2019 and to File gor CE Mark in the EU and Health Canada Approval in Early 2019 LOS ANGELES, CA / ACCESSWIRE / December 4, 2018 ...

  • ACCESSWIRE3 months ago

    DECN CEO Keith M. Berman Is Interviewed By Prestigious Wall Street Reporter Who Describe Company And Products As ''Game Changer''

    Wall Street Reporter Posts Interview On Its Web Site For All Interested Parties To Listen And To Learn About The Vast Potential Of Decn LOS ANGELES, CA / ACCESSWIRE / November 27, 2018 / Decision Diagnostics ...

  • ACCESSWIRE3 months ago

    DECN Receives Completed Clinical Trial Data, Charts and Spreadsheets Essential for its Imminent Genchoice! Test Strip

    LOS ANGELES, CA / ACCESSWIRE / November 6, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16-year-old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and the clinical trial in process concluded GenChoice! ("Ladybug"), the new PetSure! test strip for the diabetic testing of dogs and cats, and the panacea GenPrecis! ("Dragonfly") diabetes testing system, ready for clinical trials. DECN reports that the CEO Keith Berman has received the concluded patient clinical trial study, managed through its partner The Bio Co., Ltd in South Korea.

  • ACCESSWIRE4 months ago

    DECN Set to Appeal the Clearly Unfair Ruling in Court's Termination of the DECN Patent Infringement and False Advertising Case Battle with Johnson & Johnson

    LOS ANGELES, CA / ACCESSWIRE / October 30, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and the clinical trial in process GenChoice! ("Ladybug"). Last week DECH found itself on the wrong side of an inaccurate and unfair ruling by the Nevada Federal District Court in its long running patent battle with industry giant Johnson & Johnson (J&J). Specifically, the Court modified the questions at issue 10 months after the conclusion of the briefings and oral arguments.

  • ACCESSWIRE5 months ago

    DECN Board Of Directors In Final Review Of Preliminary Financing Agreement For $4.75 Million Investment

    LOS ANGELES, CA / ACCESSWIRE / September 13, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA ...

  • ACCESSWIRE5 months ago

    DECN Announces Major Step Ahead with Offering Statement

    LOS ANGELES, CA / ACCESSWIRE / September 6, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) (the "Company") is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, the clinical trial in process GenChoice! ("Ladybug") test strip, the market ready PetSure! test strip for the diabetic testing of dogs and cats, and the GenPrecis! ("Dragonfly") diabetes testing system, ready for clinical trials. Decision Diagnostics is pleased to announce that the Securities and Exchange Commission ("SEC") Staff completed its initial review of our proposed offering under Regulation A, for up to $7.5 million, by sending a "no comment" letter.

  • ACCESSWIRE6 months ago

    DECN Announces Significant Updates For Products And Programs

    Company Discusses Its Gensure!, Genchoice And, Genprecis Products, The Genprecis Precise Meter, And The New Petsure And, Petultimate Products And Petultimate Avantage Meter, Plus Our Big Box Hybrid Private ...

  • ACCESSWIRE6 months ago

    DECN Makes Its Mark In $1+ Billion Dollar Pet Diabetes & Glucose Testing Market With Two New Products, Petsure! & Petultimate!

    Petsure! Test Strips Currently On Sale Commercially With New Proprietary Petultimate! Test Strips And Avantage! Meter To Be In Distribution Early In 4th Quarter LOS ANGELES, CA / ACCESSWIRE / August 7, ...

  • ACCESSWIRE7 months ago

    Decision Diagnostics Corp. Announces Election of Two Key Managers to the Board of Its Korean Partner ''The Bio Co, Ltd.''

    LOS ANGELES, CA / ACCESSWIRE / July 12, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and the clinical trial in process GenChoice! ("Ladybug"), the market ready PetSure! test strip for the diabetic testing of dogs and cats, and the panacea GenPrecis! ("Dragonfly") diabetes testing system, ready for clinical trials. Decision Diagnostics is excited to announce that two key executives, CEO Keith Berman and exclusive agent to DECN for Asia Daniel Y. Kim, have been elected to the Board of Directors of The Bio Co. Ltd., the company's partner for the manufacturing of and development of its test strips and meters.

  • ACCESSWIRE10 months ago

    Decision Diagnostics (DECN) Contemplates Additional Legal Actions Against Longtime Adversary Johnson & Johnson (JNJ)

    LOS ANGELES, CA / ACCESSWIRE / April 18, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 16 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and the clinical trial ready GenChoice! ("Ladybug") and the panacea GenPrecis! ("Dragonfly") diabetes testing system. Today the Company announced it is contemplating the pendency of additional legal proceedings in Federal court against Johnson and Johnson (JNJ) in addition to the current patent litigation. J&J's contemplated near-term sale of its Lifescan divisions (the subject of the current lawsuits), for which there is a firm offer by a major investor, raises potential issues of J&J trying to escape the judgment of millions of dollars of damages brought against them in our current patent infringement suit.

  • ACCESSWIRE11 months ago

    Decision Diagnostics Discusses Culmination of Patent Case Against J&J and Its Divisions Based on The Federal Doctrine of Equivalents

    DECN Believes that Health Industry Giant is Employing Very Risky Summary Judgment Strategy in $400 Million Case LOS ANGELES, CA / ACCESSWIRE / March 27, 2018 / Decision Diagnostics Corp. (OTC PINK: DECN ...

  • ACCESSWIRE11 months ago

    Decision Diagnostics' Panacea Genprecis! Product Moves into Pre-Production, First Round Clinical Trials to Begin in the Next 30 Days

    Initial Testing Proves DECN's GenPrecis! System is Performing Above and Beyond Published Standards, Looking Toward Becoming an Industry Legacy in its Own Right LOS ANGELES, CA / ACCESSWIRE / March 21, ...

  • ACCESSWIRE11 months ago

    Decision Diagnostics' Fundamental Genchoice! Diabetic Test Strip Moves into Formal Managed Clinical Trials and Advanced Testing for Upcoming 510k Filing with U.S. FDA

    DECN Anticipates Initial International Sales of 165,000 Genchoice! B oxes Per Month as it also Readies Panacea Genprecis! System, and as Hybrid Private Label Plan Reaches Intensity LOS ANGELES, CA / ACCESSWIRE ...